Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in …

Currently, different radiometals are in use for imaging and therapy in nuclear medicine:
68Ga and 111In are examples of nuclides for positron emission tomography (PET) and …

Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Prostate-specific membrane antigen (PSMA)–targeted radiopharmaceuticals are playing a
large role at the time of initial staging and biochemical recurrence for localizing prostate …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Purpose Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting
tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide …